The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis

BACKGROUND: Alectinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor approved by the US Food and Drug Administration to treat crizotinib-refractory non-small cell lung cancer. We performed this meta-analysis to synthesize the results of different clinical trials to evaluate the ef...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Onco Targets Ther
Autors principals: Fan, Junsheng, Xia, Zengfei, Zhang, Xiaoli, Chen, Yuqing, Qian, Ruolan, Liu, Sihan, You, Danming, Zhang, Jian, Luo, Peng
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2018
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5840301/
https://ncbi.nlm.nih.gov/pubmed/29535535
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S156170
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars